ADRB2 and asthma: In conclusion, based on the data derived from the included studies, this systematic review and meta-analysis indicated that ArgGly polymorphism of ADRB2 may not be a predictive genetic marker of pulmonary function response to LABAs plus ICS treatment in asthma patients.